The ribonuclease L-dependent antiviral roles of human 2',5'-oligoadenylate synthetase family members against hepatitis C virus (Q39235700)

10 September 2017

The ribonuclease L-dependent antiviral roles of human 2',5'-oligoadenylate synthetase family members against hepatitis C virus (English)

1 reference

10 September 2017

1 reference

1 reference

Young-Chan Kwon

1

1 reference

10 September 2017

Ju-Il Kang

series ordinal

2

1 reference

10 September 2017

Soon B Hwang

series ordinal

3

1 reference

10 September 2017

Byung-Yoon Ahn

series ordinal

4

1 reference

10 September 2017

language of work or name

English

0 references

publication date

26 November 2012

1 reference

10 September 2017

1 reference

10 September 2017

587

1 reference

10 September 2017

2

1 reference

10 September 2017

156-164

1 reference

New insights into the role of RNase L in innate immunity

10 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Small self-RNA generated by RNase L amplifies antiviral innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

The human 2'-5'oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2'-5' instead of 3'-5' phosphodiester bond formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Replication of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Nonlinear partial differential equations and applications: Genomic analysis of the host response to hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Complete replication of hepatitis C virus in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

PKR protein kinase is activated by hepatitis C virus and inhibits viral replication through translational control

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Modulation of the type I interferon pathways by culture-adaptive hepatitis C virus core mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Newcastle disease virus V protein is a determinant of host range restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Development and characterization of a transient-replication assay for the genotype 2a hepatitis C virus subgenomic replicon

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Ribosomal RNA cleavage, nuclease activation and 2-5A (ppp(A2′p)nA) in interferon-treated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Mapping of the human RNASEL promoter and expression in cancer and normal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Basis for regulated RNA cleavage by functional analysis of RNase L and Ire1p

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Variation in antiviral 2',5'-oligoadenylate synthetase (2'5'AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Genetic Variation in OAS1 Is a Risk Factor for Initial Infection with West Nile Virus in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

69-kDa and 100-kDa isoforms of interferon-induced (2'-5')oligoadenylate synthetase exhibit differential catalytic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Distinct antiviral roles for human 2',5'-oligoadenylate synthetase family members against dengue virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

Activation of the 2-5OAS/RNase L pathway in CVB1 or HAV/18f infected FRhK-4 cells does not require induction of OAS1 or OAS2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2012.11.010

10.1016/J.FEBSLET.2012.11.010

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference